Arcus Biosciences, Inc. (RCUS) announced on Wednesday a clinical trial collaboration with AstraZeneca (AZN) to assess the combination of casdatifan and volrustomig for treating clear cell renal cell carcinoma (ccRCC).
"Renal cell carcinoma is recognized as a tumor type responsive to CTLA-4, and our initial study with volrustomig monotherapy has shown promising efficacy in first-line advanced ccRCC," stated Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca.
As part of this collaboration, AstraZeneca will be responsible for sponsoring and conducting a study aimed at evaluating the safety and preliminary efficacy of this combination therapy in patients with advanced ccRCC.
